{"ATC Code":"A - Alimentary tract and metabolism","Abbreviation":"","Aliases":["L-Hyoscyamine","Daturine","(-)-Hyoscyamine","Duboisine","(-)-Atropine","L-Tropine tropate","(S)-(-)-Hyoscyamine","Cystospaz","l-Atropine","(S)-Atropine"],"Biological Half-Life":"The half life of hyoscyamine is 3.5 hours.","CAS":"101-31-5","ChEBI":"CHEBI:17486","ChEMBL":"CHEMBL1234973","ChemicalClasses":["piperidine"],"Chirality":"absolute","Color/Form":"SILKY, TETRAGONAL NEEDLES FROM EVAPORATING ALCOHOL","Dosing Info":[],"Drug Classes":"Gastrointestinal Agents","Drug Indication":"As a drug that is not FDA approved, hyscyamine has no official indications. Intravenous hysocyamine has been used to reduce gastric motility, reduce pancreatic pain and secretions, to facilitate imaging of the gastrointestinal tract, treat anticholinesterase toxicity, treat certain cases of partial heart block, improve visualization of the kidneys, and for symptomatic relief of biliary and renal colic. Intravenous hyoscyamine is also used pre-operatively to reduce secretions of the mouth and respiratory tract to facilitate intubation. Oral hyoscyamine is used to treat functional intestinal disorders, for symptomatic relief of biliary and renal colic, and symptomatic relief of acute rhinitis.","DrugClasses":[],"European Community (EC) Number":"202-933-0","Human Drugs":"Pharmaceuticals","IUPACName":"[(1S,5R)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] (2S)-3-hydroxy-2-phenylpropanoate","InChI":"InChI=1S/C17H23NO3/c1-18-13-7-8-14(18)10-15(9-13)21-17(20)16(11-19)12-5-3-2-4-6-12/h2-6,13-16,19H,7-11H2,1H3/t13-,14+,15?,16-/m1/s1","InChIKey":"RKUNBYITZUJHSG-VFSICIBPSA-N","MeSH Pharmacological Classification":"Agents that cause an increase in the expansion of a bronchus or bronchial tubes. (See all compounds classified as Bronchodilator Agents.)","Melting Point":"108.5 °C","MolecularFormula":"C\u003csub\u003e17\u003c/sub\u003eH\u003csub\u003e23\u003c/sub\u003eNO\u003csub\u003e3\u003c/sub\u003e","MolecularWeight":"289.4 g/mol","Opticalactivity":"( - )","Pharmacodynamics":"Hyoscyamine is not FDA approved, and so it has not official indications. However, it is used as an antimuscarinic agent in a number of treatments and therapies. Hyoscyamine has a short duration of action as it may need to be given multiple times per day. Patients should be counselled regarding the risks and signs of anticholinergic toxicity.","PubChemId":154417,"Record Description":["(S)-atropine is an atropine with a 2S-configuration. It is functionally related to a (S)-tropic acid. It is a conjugate base of a (S)-atropinium.","Hyoscyamine is a tropane alkaloid and the levo-isomer of [atropine]. It is commonly extracted from plants in the Solanaceae or nightshade family. Research into the action of hyoscyamine in published literature dates back to 1826. Hyoscyamine is used for a wide variety of treatments and therapeutics due to its antimuscarinic properties.  Although hyoscyamine is marketed in the United States, it is not FDA approved.","Hyoscyamine as a natural plant alkaloid derivative and anticholinergic that is used to treat mild to moderate nausea, motion sickness, hyperactive bladder and allergic rhinitis. Hyoscyamine has not been implicated in causing liver enzyme elevations or clinically apparent acute liver injury.","L-Hyoscyamine has been reported in Scopolia parviflora, Cyphanthera odgersii, and other organisms with data available.","Hyoscyamine is a belladonna alkaloid derivative and the levorotatory form of racemic atropine isolated from the plants Hyoscyamus niger or Atropa belladonna, which exhibits anticholinergic activity. Hyoscyamine functions as a non-selective, competitive antagonist of muscarinic receptors, thereby inhibiting the parasympathetic activities of acetylcholine on the salivary, bronchial, and sweat glands, as well as the eye, heart, bladder, and gastrointestinal tract. These inhibitory effects cause a decrease in saliva, bronchial mucus, gastric juices, and sweat. Furthermore, its inhibitory action on smooth muscle prevents bladder contraction and decreases gastrointestinal motility.","HYOSCYAMINE is a small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for urinary tract infection and gastrointestinal disease.","The 3(S)-endo isomer of atropine.","See also: Atropine (annotation moved to); Hyoscyamine (annotation moved to).","(S)-atropine is an atropine with a 2S-configuration. It is functionally related to a (S)-tropic acid. It is a conjugate base of a (S)-atropinium.","LiverTox|Gastroinestinal|Antispasmotic|Anticholinergic"],"References":[{"name":"Wikipedia","url":"https://en.wikipedia.org/wiki/Hyoscyamine"},{"name":"Wikidata","url":"https://www.wikidata.org/wiki/Q104391780"},{"name":"DrugBank","url":"https://go.drugbank.com/drugs/DB00424"},{"name":"PubChem","url":"https://pubchem.ncbi.nlm.nih.gov/compound/154417"},{"name":"ChemSpider","url":"https://www.chemspider.com/Chemical-Structure.21108562.html"},{"name":"ChEMBL","url":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1234973"},{"name":"ChEBI","url":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:17486"},{"name":"Common Chemistry","url":"https://commonchemistry.cas.org/detail?cas_rn=101-31-5"},{"name":"KEGG","url":"https://www.kegg.jp/entry/C02046"},{"name":"UNII","url":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/PX44XO846X"},{"name":"EPA DSSTox","url":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID20941522"}],"Reported Fatal Dose":"6. 6= SUPER TOXIC: PROBABLE ORAL LETHAL DOSE (HUMAN) LESS THAN 5 MG/KG; A TASTE (LESS THAN 7 DROPS) FOR 70 KG PERSON (150 LB).","SMILES":"CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)[C@H](CO)C3=CC=CC=C3","Salts":["hydrochloride","sulfate"],"Solubility":"1 G DISSOLVES IN 281 ML OF WATER (PH 9.5), 69 ML OF ETHER, 150 ML OF BENZENE, 1 ML OF CHLOROFORM; FREELY SOL IN ALCOHOL, DIL ACIDS","Stability/Shelf Life":"AFFECTED BY LIGHT \u0026 HEAT","StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="56.917mm" version="1.2" viewBox="0 0 117.87 56.917" width="117.87mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#FF0D0D" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="57.0" stroke="none" width="118.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <line class="bond" id="mol1bnd1" x1="2.523" x2="14.423" y1="29.478" y2="29.478"/>
                  
            <g class="bond" id="mol1bnd2">
                        
                <line stroke="#000000" x1="25.08" x2="25.687" y1="42.861" y2="42.511"/>
                        
                <line stroke="#3050F8" x1="23.775" x2="24.815" y1="41.099" y2="40.499"/>
                        
                <line stroke="#3050F8" x1="22.47" x2="23.943" y1="39.337" y2="38.487"/>
                        
                <line stroke="#3050F8" x1="21.165" x2="23.071" y1="37.575" y2="36.475"/>
                        
                <line stroke="#3050F8" x1="19.86" x2="22.199" y1="35.813" y2="34.463"/>
                        
                <line stroke="#3050F8" x1="18.555" x2="21.327" y1="34.051" y2="32.452"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd3" x1="25.383" x2=".96" y1="42.686" y2="38.885"/>
                  
            <line class="bond" id="mol1bnd4" x1=".96" x2=".96" y1="38.885" y2="20.07"/>
                  
            <line class="bond" id="mol1bnd5" x1=".96" x2="25.383" y1="20.07" y2="16.27"/>
                  
            <g class="bond" id="mol1bnd6">
                        
                <line stroke="#000000" x1="25.687" x2="25.08" y1="16.445" y2="16.095"/>
                        
                <line stroke="#3050F8" x1="24.815" x2="23.775" y1="18.456" y2="17.857"/>
                        
                <line stroke="#3050F8" x1="23.943" x2="22.47" y1="20.468" y2="19.618"/>
                        
                <line stroke="#3050F8" x1="23.071" x2="21.165" y1="22.48" y2="21.38"/>
                        
                <line stroke="#3050F8" x1="22.199" x2="19.86" y1="24.492" y2="23.142"/>
                        
                <line stroke="#3050F8" x1="21.327" x2="18.555" y1="26.504" y2="24.904"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd7" x1="25.383" x2="40.623" y1="16.27" y2="16.27"/>
                  
            <line class="bond" id="mol1bnd8" x1="40.623" x2="48.243" y1="16.27" y2="29.478"/>
                  
            <line class="bond" id="mol1bnd9" x1="48.243" x2="40.623" y1="29.478" y2="42.686"/>
                  
            <line class="bond" id="mol1bnd10" x1="25.383" x2="40.623" y1="42.686" y2="42.686"/>
                  
            <line class="bond" id="mol1bnd11" x1="48.243" x2="59.824" y1="29.478" y2="29.478"/>
                  
            <line class="bond" id="mol1bnd12" x1="65.451" x2="71.103" y1="26.069" y2="16.279"/>
                  
            <g class="bond" id="mol1bnd13">
                        
                <line x1="70.4" x2="64.394" y1="17.499" y2="7.097"/>
                        
                <line x1="72.511" x2="66.506" y1="16.279" y2="5.878"/>
                      
                <line class="hi" stroke="#FF0D0D" x1="64.394" x2="67.397" y1="7.097000000000001" y2="12.298"/>
                <line class="hi" stroke="#FF0D0D" x1="66.506" x2="69.5085" y1="5.878" y2="11.0785"/>
            </g>
                  
            <line class="bond" id="mol1bnd14" x1="71.103" x2="86.343" y1="16.279" y2="16.279"/>
                  
            <g class="bond" id="mol1bnd15">
                        
                <line x1="86.694" x2="85.993" y1="16.279" y2="16.279"/>
                        
                <line x1="88.255" x2="86.972" y1="14.08" y2="14.08"/>
                        
                <line x1="89.817" x2="87.95" y1="11.88" y2="11.88"/>
                        
                <line x1="91.379" x2="88.928" y1="9.68" y2="9.68"/>
                        
                <line x1="92.94" x2="89.907" y1="7.481" y2="7.481"/>
                        
                <line x1="94.502" x2="90.885" y1="5.281" y2="5.281"/>
                        
                <line x1="96.064" x2="91.863" y1="3.081" y2="3.081"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd16" x1="93.963" x2="105.544" y1="3.081" y2="3.081"/>
                  
            <line class="bond" id="mol1bnd17" x1="86.343" x2="93.963" y1="16.279" y2="29.478"/>
                  
            <g class="bond" id="mol1bnd18">
                        
                <line x1="109.212" x2="93.963" y1="29.473" y2="29.478"/>
                        
                <line x1="107.804" x2="95.371" y1="31.912" y2="31.916"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd19" x1="109.212" x2="116.832" y1="29.473" y2="42.671"/>
                  
            <g class="bond" id="mol1bnd20">
                        
                <line x1="109.203" x2="116.832" y1="55.874" y2="42.671"/>
                        
                <line x1="107.796" x2="114.016" y1="53.436" y2="42.67"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd21" x1="109.203" x2="93.955" y1="55.874" y2="55.879"/>
                  
            <g class="bond" id="mol1bnd22">
                        
                <line x1="86.335" x2="93.955" y1="42.681" y2="55.879"/>
                        
                <line x1="89.151" x2="95.363" y1="42.681" y2="53.44"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd23" x1="93.963" x2="86.335" y1="29.478" y2="42.681"/>
                  
            <path class="atom" d="M19.704 31.927h-.72l-2.62 -4.066h-.029q.012 .238 .029 .596q.024 .357 .024 .732v2.738h-.565v-4.899h.714l2.608 4.054h.029q-.006 -.107 -.018 -.327q-.011 -.221 -.023 -.477q-.006 -.262 -.006 -.482v-2.768h.577v4.899z" fill="#3050F8" id="mol1atm2" stroke="none"/>
                  
            <path class="atom" d="M65.743 29.475q-.0 .756 -.256 1.327q-.256 .566 -.756 .881q-.5 .316 -1.245 .316q-.756 -.0 -1.262 -.316q-.506 -.315 -.756 -.887q-.244 -.571 -.244 -1.333q.0 -.75 .244 -1.31q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.733 .0 1.233 .316q.5 .31 .756 .875q.256 .566 .256 1.328zM61.879 29.475q.0 .922 .387 1.458q.393 .53 1.22 .53q.84 -.0 1.221 -.53q.387 -.536 .387 -1.458q-.0 -.929 -.387 -1.453q-.381 -.524 -1.209 -.524q-.833 .0 -1.226 .524q-.393 .524 -.393 1.453z" id="mol1atm10" stroke="none"/>
                  
            <path class="atom" d="M65.743 3.078q-.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .315 -1.245 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q.0 -.75 .244 -1.309q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.733 -.0 1.233 .316q.5 .309 .756 .875q.256 .565 .256 1.327zM61.879 3.078q.0 .923 .387 1.459q.393 .53 1.22 .53q.84 -.0 1.221 -.53q.387 -.536 .387 -1.459q-.0 -.929 -.387 -1.452q-.381 -.524 -1.209 -.524q-.833 -.0 -1.226 .524q-.393 .523 -.393 1.452z" id="mol1atm12" stroke="none"/>
                  
            <g class="atom" id="mol1atm15">
                        
                <path d="M111.463 3.078q-.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .315 -1.245 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q.0 -.75 .244 -1.309q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.733 .0 1.233 .316q.5 .309 .756 .875q.256 .565 .256 1.327zM107.599 3.078q.0 .923 .387 1.459q.393 .53 1.22 .53q.84 -.0 1.221 -.53q.387 -.536 .387 -1.459q-.0 -.929 -.387 -1.452q-.381 -.524 -1.209 -.524q-.833 -.0 -1.226 .524q-.393 .523 -.393 1.452z" stroke="none"/>
                        
                <path d="M115.769 5.531h-.619v-2.286h-2.512v2.286h-.614v-4.9h.614v2.072h2.512v-2.072h.619v4.9z" stroke="none"/>
                      
            </g>
                
            <line class="hi" id="mol1bnd1" stroke="#3050F8" x1="14.423" x2="8.473" y1="29.478" y2="29.478"/>
            <line class="hi" id="mol1bnd11" stroke="#FF0D0D" x1="59.824" x2="54.033500000000004" y1="29.478" y2="29.478"/>
            <line class="hi" id="mol1bnd12" stroke="#FF0D0D" x1="65.451" x2="68.27699999999999" y1="26.069" y2="21.174"/>
            <line class="hi" id="mol1bnd16" stroke="#FF0D0D" x1="105.544" x2="99.7535" y1="3.081" y2="3.081"/>
        </g>
          
    </g>
    
</svg>
","Therapeutic Uses":"Adjuvants, Anesthesia; Anti-Arrhythmia Agents; Antidotes; Bronchodilator Agents; Muscarinic Antagonists; Mydriatics; Parasympatholytics","Title":"Hyoscyamine","UNII":"PX44XO846X","Wikidata":"Q104391780","XLogP":1.8}